Aksel Siva (EAN Programme Committee; Professor of Neurology, Istanbul University, Cerrahpasa School of Medicine, Turkey) talks to us about various treatment considerations in multiple sclerosis (MS): induction, individualised therapy, optimal therapeutic window and when to switch therapies. Part 1 of 2.
1. What are the limitations of using induction therapy in multiple sclerosis (MS)? (0:12)
2. Given the lack of biomarkers, what features of MS do you consider most important to establish an individual treatment regimen? (3:23)
View Part 2 here.
Speaker disclosure: Aksel Siva has nothing to disclose in relation to this video interview.
Filmed at the 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, June 2018.
Share this Video
Related Videos In Multiple Sclerosis
Barry Singer, ECTRIMS 2021: Flushing and Flushing-related Adverse Events – Results from the Phase 3 EVOLVE-MS-2 Study
It was a pleasure to meet with Dr Barry Singer (The MS Center for Innovations in Care, Missouri Baptist Medical Center, St. Louis, MO, USA) to discuss the results of the phase 3 EVOLVE-MS-2 study, specifically looking at flushing and flushing related-adverse events with diroximel fumarate in patients with relapsing remitting multiple sclerosis. The abstract […]
Lawrence Steinman, EAN 2021: Hot Topics in Multiple Sclerosis
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA) to discuss some of the hot topics and research trends in the field of multiple sclerosis for 2021/22. Question: What are the hot topics and latest research […]
Lawrence Steinman EAN, 2021: Results from the Phase 3 ULTIMATE I and II Trials
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA), to discuss the results from the Phase 3 ULTIMATE I and II trials, investigating ublituximab versus teriflunomide in relapsing multiple sclerosis. The abstract entitled: ‘Ublituximab versus teriflunomide […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!